{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:41:20Z","timestamp":1776764480677,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-026-08426-y","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:49:40Z","timestamp":1776761380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia: a retrospective cohort study"],"prefix":"10.1007","volume":"313","author":[{"given":"K.","family":"Eissler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Engler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Dannehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sch\u00f6nfisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Englisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D.","family":"Hartkopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Y.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"Grischke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. L.","family":"Volmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Englisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"8426_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199504063321401","volume":"332","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna G, Valagussa P, Moliterni A et al (1995) Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in node-positive breast cancer \u2014 the results of 20 years of follow-up. N Engl J Med 332:901\u2013906. https:\/\/doi.org\/10.1056\/NEJM199504063321401","journal-title":"N Engl J Med"},{"key":"8426_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","volume":"330","author":"G Bonadonna","year":"2005","unstructured":"Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years\u2019 follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217. https:\/\/doi.org\/10.1136\/bmj.38314.622095.8F","journal-title":"BMJ"},{"key":"8426_CR3","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1200\/JCO.2005.05.059","volume":"23","author":"J Bonneterre","year":"2005","unstructured":"Bonneterre J, Roch\u00e9 H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686\u20132693. https:\/\/doi.org\/10.1200\/JCO.2005.05.059","journal-title":"J Clin Oncol"},{"key":"8426_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly A, Bron D, Van Hoof A et al (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277\u2013283. https:\/\/doi.org\/10.1007\/s00277-007-0399-y","journal-title":"Ann Hematol"},{"key":"8426_CR5","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/sj.bjc.6601279","volume":"89","author":"RCF Leonard","year":"2003","unstructured":"Leonard RCF, Miles D, Thomas R, Nussey F (2003) Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89:2062\u20132068. https:\/\/doi.org\/10.1038\/sj.bjc.6601279","journal-title":"Br J Cancer"},{"key":"8426_CR6","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW et al (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555\u20135563. https:\/\/doi.org\/10.1002\/cncr.25332","journal-title":"Cancer"},{"key":"8426_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-017-4646-1","volume":"169","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu Q, Wu X-C et al (2018) Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat 169:175\u2013187. https:\/\/doi.org\/10.1007\/s10549-017-4646-1","journal-title":"Breast Cancer Res Treat"},{"key":"8426_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.21873\/anticanres.14863","volume":"41","author":"A Yamada","year":"2021","unstructured":"Yamada A, Nakazawa K, Akazawa K et al (2021) Impact of the relative dose intensity of neoadjuvant chemotherapy with anthracycline followed by taxane on the survival of patients with Human Epidermal Growth Factor Receptor 2-negative breast cancer: the JONIE1 study. Anticancer Res 41:1063\u20131068. https:\/\/doi.org\/10.21873\/anticanres.14863","journal-title":"Anticancer Res"},{"key":"8426_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299\u20131309. https:\/\/doi.org\/10.1007\/s00520-008-0430-4","journal-title":"Support Care Cancer"},{"key":"8426_CR10","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266. https:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"key":"8426_CR11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/sj.bjc.6690583","volume":"80","author":"S Kvinnsland","year":"1999","unstructured":"Kvinnsland S (1999) The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 80:1681. https:\/\/doi.org\/10.1038\/sj.bjc.6690583","journal-title":"Br J Cancer"},{"key":"8426_CR12","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/sj.bjc.6601366","volume":"89","author":"DA Cameron","year":"2003","unstructured":"Cameron DA, Massie C, Kerr G, Leonard RCF (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89:1837\u20131842. https:\/\/doi.org\/10.1038\/sj.bjc.6601366","journal-title":"Br J Cancer"},{"key":"8426_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000313702","volume":"78","author":"M Ishitobi","year":"2010","unstructured":"Ishitobi M, Komoike Y, Motomura K et al (2010) Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer. Oncology 78:213\u2013219. https:\/\/doi.org\/10.1159\/000313702","journal-title":"Oncology"},{"key":"8426_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-011-1799-1","volume":"131","author":"Y Han","year":"2012","unstructured":"Han Y, Yu Z, Wen S et al (2012) Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res Treat 131:483\u2013490. https:\/\/doi.org\/10.1007\/s10549-011-1799-1","journal-title":"Breast Cancer Res Treat"},{"key":"8426_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-026-08317-2","volume":"313","author":"A Englisch","year":"2026","unstructured":"Englisch A, Eissler K, Dannehl D et al (2026) Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface area. Arch Gynecol Obstet 313:75. https:\/\/doi.org\/10.1007\/s00404-026-08317-2","journal-title":"Arch Gynecol Obstet"},{"key":"8426_CR16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","volume":"2","author":"W Hryniuk","year":"1984","unstructured":"Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281\u20131288. https:\/\/doi.org\/10.1200\/JCO.1984.2.11.1281","journal-title":"J Clin Oncol"},{"key":"8426_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-131","volume":"11","author":"S Loibl","year":"2011","unstructured":"Loibl S, Skacel T, Nekljudova V et al (2011) Evaluating the impact of relative total dose intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 11:131. https:\/\/doi.org\/10.1186\/1471-2407-11-131","journal-title":"BMC Cancer"},{"key":"8426_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-013-2582-2","volume":"139","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Tomita D et al (2013) A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat 139:863\u2013872. https:\/\/doi.org\/10.1007\/s10549-013-2582-2","journal-title":"Breast Cancer Res Treat"},{"key":"8426_CR19","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4143\/crt.2020.928","volume":"53","author":"KH Lee","year":"2021","unstructured":"Lee KH, Chie EK, Im SA et al (2021) Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine in patients with resected pancreatic cancer. Cancer Res Treat 53:1096\u20131103. https:\/\/doi.org\/10.4143\/crt.2020.928","journal-title":"Cancer Res Treat"},{"key":"8426_CR20","unstructured":"U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE)"},{"key":"8426_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70187-8","volume":"10","author":"W Qi","year":"2020","unstructured":"Qi W, Wang X, Gan L et al (2020) The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. Sci Rep 10:13241. https:\/\/doi.org\/10.1038\/s41598-020-70187-8","journal-title":"Sci Rep"},{"key":"8426_CR22","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00280-012-1872-4","volume":"69","author":"T Uchiyama","year":"2012","unstructured":"Uchiyama T, Kanno H, Ishitani K et al (2012) An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel. Cancer Chemother Pharmacol 69:1617\u20131624. https:\/\/doi.org\/10.1007\/s00280-012-1872-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"8426_CR23","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1158\/1078-0432.CCR-20-4774","volume":"28","author":"PA Fasching","year":"2022","unstructured":"Fasching PA, Liu D, Scully S et al (2022) Identification of two genetic loci associated with leukopenia after chemotherapy in patients with breast cancer. Clin Cancer Res 28:3342\u20133355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4774","journal-title":"Clin Cancer Res"},{"key":"8426_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","volume":"29","author":"M Ewertz","year":"2011","unstructured":"Ewertz M, Jensen M-B, Gunnarsd\u00f3ttir K\u00c1 et al (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29:25\u201331. https:\/\/doi.org\/10.1200\/JCO.2010.29.7614","journal-title":"J Clin Oncol"},{"key":"8426_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.4236\/jct.2019.1012075","volume":"10","author":"A Morsy","year":"2019","unstructured":"Morsy A, Shehata S (2019) The effect of body mass index on survival in breast cancer. J Cancer Ther 10:883\u2013894. https:\/\/doi.org\/10.4236\/jct.2019.1012075","journal-title":"J Cancer Ther"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08426-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08426-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08426-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:49:42Z","timestamp":1776761382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08426-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8426"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08426-y","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AE: Honoraria from Novartis and AstraZeneca; DD: Honoraria from AstraZeneca, Gilead, Novartis, Daiichi Sankyo, Onkowissen, Oncologics, and Pfizer; travel support from Gilead and Daiichi Sankyo; JE: Honoraria from AstraZeneca; ADH: Speakers bureau for Roche, Novartis, Lilly, MSD, AstraZeneca, Daiichi Sankyo, Seagen, GSK, ExactScience, Gilead, Menarini Stemline, Pfizer, and Eisai. Honoraria from Roche, Novartis, Lilly, MSD, AstraZeneca, Seagen, GSK, ExactScience, Riemser, Teva, Onkowissen, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, Eisai, and Daiichi Sankyo. Consulting\/advisory role for Roche, Novartis, MSD, AstraZeneca, GSK, ExactScience, Riemser, Teva, Onkowissen, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, and Daiichi Sankyo. Travel support from Roche, Novartis, Lilly, AstraZeneca, GSK, ExactScience, Gilead, Menarini Stemline, Pfizer, and Daiichi Sankyo. Research grants from ExactScience and Veracyte. Authorship honoraria from AstraZeneca and Menarini Stemline; SYB: Honoraria from Roche, Novartis, Pfizer, MSD, Teva, and AstraZeneca; LLV: Honoraria from Novartis; TE: Honoraria from Abbvie, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, GSK, MSD, Novartis, Pfizer, Pierre Fabre, and Roche. Consulting\/advisory role for AstraZeneca, Eli Lilly, Gilead, GSK, MSD, Novartis, Pfizer, Pierre Fabre, Roche, and Stemline. Travel support from Abbvie, Eli Lilly, Gilead, Novartis, Pfizer, and Stemline. All remaining authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"170"}}